At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 44 enrolled
Drug / intervention
Celecoxib +3 moredrug
Likely dose
Celecoxib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment (ASCENT)
In Brief
A Phase 4 clinical trial evaluating Celecoxib, Placebo, and 2 other interventions for Healthy. Completed, enrolled 44 participants across 1 site.
Detailed Summary
A single centre, placebo controlled, blinded (participant, investigator, outcome assessor) trial to evaluate the effects of COX-2 inhibition with celecoxib on endothelial function in healthy male volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartJun 2021
Primary CompletionJan 2022
TodayJul 2026
First PostedFeb 21, 2021
Enrollment StartJun 10, 2021
Primary CompletionJan 24, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.4 years ago
Interventions
Celecoxibdrug
Two 200 mg capsules per day (400 mg/day) for 7 days
Placeboother
2 capsules/day for 7 days
L-arginine + placeboother
L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
L-arginine + celecoxibother
L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days